BWXT owns real choke points in a tightening nuclear supply chain, so revenue should outgrow most industrial peers as naval work,
special materials, commercial services and medical programs scale. But this is already a premium-rated strategic asset. I expect steady shareholder compounding, not another dramatic
rerating, because the next leg up requires visible
backlog conversion, clean integration and proof that adjacent fuel options become cash earnings.